e-learning
resources
Vienna 2012
Tuesday, 04.09.2012
Pros and cons of MDR- and XDR-TB treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Adverse reactions during treatment of multidrug-resistant and extensively drug-resistant tuberculosis
S. Boavida, I. Sanches, A. Antunes, S. Campainha, A. Horta, A. M. Correia, A. Silva, R. Duarte (Porto, Coimbra, Portugal)
Source:
Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment
Session:
Pros and cons of MDR- and XDR-TB treatment
Session type:
Oral Presentation
Number:
4292
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Boavida, I. Sanches, A. Antunes, S. Campainha, A. Horta, A. M. Correia, A. Silva, R. Duarte (Porto, Coimbra, Portugal). Adverse reactions during treatment of multidrug-resistant and extensively drug-resistant tuberculosis. Eur Respir J 2012; 40: Suppl. 56, 4292
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Adverse events in the treatment of multidrug-resistant tuberculosis
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011
Treatment options for patients with multidrug-resistant or extensively drug-resistant tuberculosis
Source: Annual Congress 2009 - Priorities in tuberculosis research
Year: 2009
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
Source: Eur Respir J 2008; 31: 1155-1159
Year: 2008
Treatment of TB
Source: Eur Respir Mon 2012; 58: 154-166
Year: 2012
Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011
Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?
Source: Eur Respir J, 55 (2) 1901908; 10.1183/13993003.01908-2019
Year: 2020
Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis
Source: Eur Respir J 2016; 47: 564-574
Year: 2016
Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis
Source: Eur Respir J, 57 (4) 2004454; 10.1183/13993003.04454-2020
Year: 2021
Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis
Source: Eur Respir J 2014; 43: 884-897
Year: 2014
Paradoxical reactions in non-HIV tuberculosis presenting as endobronchial obstruction
Source: Eur Respir Rev 2009; 18: 295-299
Year: 2009
Management and treatment of multidrug-resistant tuberculosis
Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management
Year: 2019
Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB
Source: Eur Respir J 2009; 33: 1085-1094
Year: 2009
Evaluation of treatment outcomes for multidrug-resistant tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 312s
Year: 2001
Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients
Source: Eur Respir J 2005; 26: Suppl. 49, 650s
Year: 2005
Adverse effects in patients receiving therapy for multi-drug resistant tuberculosis in Latvia
Source: Eur Respir J 2003; 22: Suppl. 45, 41s
Year: 2003
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen
Source: Eur Respir J, 52 (6) 1801528; 10.1183/13993003.01528-2018
Year: 2018
Clinical outcomes of patients with drug-resistant and extensively drug-resistant tuberculosis in Europe
Source: Annual Congress 2008 - Priorities for tuberculosis research in Europe: discussing the results of the Tuberculosis Network European Trials Group (TBNET)
Year: 2008
Risk factors for treatment failure in multidrug-resistant and extensively drug-resistant tuberculosis in Estonia
Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control
Year: 2008
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis
Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017
Year: 2017
Linezolid in the treatment of multi- and extensively drug-resistance tuberculosis
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept